Diabetes and the Prostate: Elevated Fasting Glucose, Insulin Resistance and Higher Levels of Adrenal Steroids in Prostate Cancer.
hyperglycemia
insulin resistance
prostate cancer
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
15 Nov 2022
15 Nov 2022
Historique:
received:
29
07
2022
revised:
08
11
2022
accepted:
10
11
2022
entrez:
26
11
2022
pubmed:
27
11
2022
medline:
27
11
2022
Statut:
epublish
Résumé
Although epidemiological studies suggest a lower prostate cancer incidence rate in patients with type 2 diabetes, cancer survival is markedly reduced. Underlying mechanisms that connect the two diseases are still unclear. Potential links between type 2 diabetes and prostate cancer are hallmarks of the metabolic syndrome, such as hyperglycemia and dyslipidemia. Therefore, we explored the systemic metabolism of 103 prostate cancer patients with newly diagnosed and yet untreated prostate cancer compared to 107 healthy controls, who were carefully matched for age and BMI. Here, we report that patients with prostate cancer display higher fasting blood glucose levels and insulin resistance, without changes in insulin secretion. With respect to lipid metabolism, serum triglyceride levels were lower in patients with prostate cancer. In addition, we report increased adrenal steroid biosynthesis in these patients. Our results indicate that higher fasting glucose levels in patients with prostate cancer may be explained at least in part by insulin resistance, due to the enhanced synthesis of adrenal steroids.
Identifiants
pubmed: 36431238
pii: jcm11226762
doi: 10.3390/jcm11226762
pmc: PMC9693518
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : The study was supported in part by a grant from the German Federal Ministry of Education and Research (BMBF) to the German Center for Diabetes Research (DZD e.V.).
ID : 01GI0925
Références
Int J Biol Sci. 2014 Jun 03;10(6):602-13
pubmed: 24948873
Mol Endocrinol. 2005 Dec;19(12):2943-54
pubmed: 16081517
Int J Cancer. 2009 Mar 15;124(6):1398-403
pubmed: 19058180
Eur J Endocrinol. 2004 Feb;150(2):97-104
pubmed: 14763905
J Urol. 2018 Jun;199(6):1475-1481
pubmed: 29246734
Diabetologia. 2017 Jun;60(6):1022-1032
pubmed: 28265721
Nat Med. 2021 Jan;27(1):49-57
pubmed: 33398163
Prostate. 2010 Oct 1;70(14):1540-6
pubmed: 20687228
Aging Male. 2010 Jun;13(2):87-92
pubmed: 19921964
Endocr Relat Cancer. 2016 Jun;23(6):R249-66
pubmed: 27194038
Diabetologia. 2004 Jun;47(6):1071-8
pubmed: 15164171
Cancer Med. 2016 Jun;5(6):1307-18
pubmed: 26923095
JAMA. 2006 Mar 15;295(11):1288-99
pubmed: 16537739
Endocr Relat Cancer. 2013 Sep 11;20(5):741-51
pubmed: 23959956
Clin Endocrinol (Oxf). 2011 Mar;74(3):377-83
pubmed: 21118287
Endocr Relat Cancer. 2018 Mar;25(3):L19-L22
pubmed: 29330196
Hypertension. 2013 Sep;62(3):572-8
pubmed: 23836801
Mol Metab. 2018 Feb;8:158-166
pubmed: 29249638
Mol Metab. 2018 Dec;18:42-50
pubmed: 30309776
Br J Cancer. 2018 May;118(9):1248-1254
pubmed: 29563633
Prostate Cancer Prostatic Dis. 2013 Jun;16(2):204-8
pubmed: 23459096
Curr Opin Endocrinol Diabetes Obes. 2010 Jun;17(3):247-56
pubmed: 20418720
Biochim Biophys Acta. 2013 Oct;1831(10):1518-32
pubmed: 23562839
J Natl Cancer Inst. 2008 Feb 6;100(3):170-83
pubmed: 18230794